Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.Tokyo, Japan, May 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eisai announced on May 10 that it has signed a joint research agreement with Nitto Denko Nitto Denko Corporation (日東電工株式会社 . Under the agreement terms, the two companies will collaborate in developing a transdermal transdermal /trans·der·mal/ (-der´m'l) entering through the dermis, or skin, as in administration of a drug via ointment or patch. trans·der·mal adj. Through or by way of the skin. formulation (adhesive tape) of ARICEPT, an agent for treating Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Nitto Denko, a Japanese leading liquid-crystal film manufacturer, has established various methods for drug formulation design. In particular, the company retains expertise in synthesizing adhesive materials suitable for controlled release. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion